First burns patient treated in NovoSorb BTM trial

Calzada (ASX:CZD) announced that the first burns patient has been treated for its clinical trial of NovoSorb BTM.

The middle-aged patient sustained a major burn injury, including flame burns to 75% of his total body surface area (TBSA). Full-thickness burns affected 45% of his TBSA.

The trial’s principal investigator, Dr John Greenwood of the Royal Adelaide Hospital, said the burn was a very significant injury for a patient of his age.

“His clinical course has been exemplary and today, after three weeks, he left the intensive care unit for the burns unit,” he said. “We have been closely monitoring the process of the BTM, which covers approximately 0.4 m². To date his treatment ... has progressed as planned.”

Calzada commenced the clinical trial in January, but it has been slow to get going because there have been no burns patients that meet the required criteria admitted to the hospital this year.

The goal of the trial is to assess the integration of the BTM (Biodegradable Temporising Matrix) into burn wounds, the ease of removal of the seal prior to skin grafting and the minimisation of contraction and scarring.

Calzada will use the results of the study to inform the design of a planned European burns trial.

NovoSorb BTM is Calzada subsidiary PolyNovo’s dermal scaffold. The company has also been trialling the product in applications including free-flap donor site repair surgery.

Calzada (ASX:CZD) shares were trading 4.35% higher at $0.12 as of around 2.30 pm on Friday.